Tags

Type your tag names separated by a space and hit enter

Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Lung Cancer. 2007 Dec; 58(3):369-75.LC

Abstract

This study aimed to establish the clinical significance of preoperative serum cytokeratin 19 fragment (CYFRA21-1) and Sialyl Lewis(x) (SLX) in patients with stage I non-small cell lung cancer (NSCLC). The study involved 137 patients (87 male, 50 female; median age 69 years) with completely resected stage I NSCLC. SLX, carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and CYFRA21-1 were examined. Receiver operator characteristic (ROC) curves were constructed to determine prognostic cut-off values. Among the 137 patients, we identified 30 with recurrence within 3 years. The 5-year survival rates in patients with (n=30) and without (n=107) recurrence were 14% and 81%, respectively. The serum concentrations of SLX, CEA, and CYFRA21-1 in the recurrence group were significantly higher than those in the non-recurrence group. The areas under the ROC curve (AUC) were 0.72, 0.65, 0.53, and 0.64 for SLX, CEA, SCC, and CYFRA21-1, respectively. The prognostic cut-off values were 36U/ml, 7.8ng/ml, 1.5ng/ml, and 3.2ng/ml for SLX, CEA, SCC, and CYFRA21-1, respectively. A log-rank test revealed that age, performance status, T factor, lymphatic invasion, vascular invasion, SLX, CEA, SCC, and CYFRA21-1 were all significantly associated with survival. By multivariate analysis, age, performance status, lymphatic invasion, SLX (risk ratio, 4.11) and CYFRA21-1 (risk ratio, 3.47) were independent prognostic factors. For patients positive for both CYFRA21-1 and SLX, the relative risk was 5.32 compared with patients who were negative for both markers. The 5-year survival rates were 80% in the group negative for both markers (n=86); 52% in the group positive for one of the markers (n=43); and 13% for the group positive for both markers (n=8) (p<0.001). We concluded that serum SLX and CYFRA21-1 were prognostic markers for stage I NSCLC. Their combination should contribute to the classification of stage I NSCLC patients. There is a need to consider adjuvant and neoadjuvant therapies to improve prognosis in patients positive for both tumor markers.

Authors+Show Affiliations

Department of Thoracic Surgery, Osaka City University Hospital, Osaka, Japan. m1293795@msic.med.osaka-cu.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17697728

Citation

Mizuguchi, Shinjiro, et al. "Serum Sialyl Lewis X and Cytokeratin 19 Fragment as Predictive Factors for Recurrence in Patients With Stage I Non-small Cell Lung Cancer." Lung Cancer (Amsterdam, Netherlands), vol. 58, no. 3, 2007, pp. 369-75.
Mizuguchi S, Nishiyama N, Iwata T, et al. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer. 2007;58(3):369-75.
Mizuguchi, S., Nishiyama, N., Iwata, T., Nishida, T., Izumi, N., Tsukioka, T., Inoue, K., Uenishi, T., Wakasa, K., & Suehiro, S. (2007). Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 58(3), 369-75.
Mizuguchi S, et al. Serum Sialyl Lewis X and Cytokeratin 19 Fragment as Predictive Factors for Recurrence in Patients With Stage I Non-small Cell Lung Cancer. Lung Cancer. 2007;58(3):369-75. PubMed PMID: 17697728.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. AU - Mizuguchi,Shinjiro, AU - Nishiyama,Noritoshi, AU - Iwata,Takashi, AU - Nishida,Tatsuya, AU - Izumi,Nobuhiro, AU - Tsukioka,Takuma, AU - Inoue,Kiyotoshi, AU - Uenishi,Takahiro, AU - Wakasa,Kenichi, AU - Suehiro,Shigefumi, Y1 - 2007/08/13/ PY - 2007/04/16/received PY - 2007/06/21/revised PY - 2007/07/04/accepted PY - 2007/8/19/pubmed PY - 2008/2/27/medline PY - 2007/8/19/entrez SP - 369 EP - 75 JF - Lung cancer (Amsterdam, Netherlands) JO - Lung Cancer VL - 58 IS - 3 N2 - This study aimed to establish the clinical significance of preoperative serum cytokeratin 19 fragment (CYFRA21-1) and Sialyl Lewis(x) (SLX) in patients with stage I non-small cell lung cancer (NSCLC). The study involved 137 patients (87 male, 50 female; median age 69 years) with completely resected stage I NSCLC. SLX, carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and CYFRA21-1 were examined. Receiver operator characteristic (ROC) curves were constructed to determine prognostic cut-off values. Among the 137 patients, we identified 30 with recurrence within 3 years. The 5-year survival rates in patients with (n=30) and without (n=107) recurrence were 14% and 81%, respectively. The serum concentrations of SLX, CEA, and CYFRA21-1 in the recurrence group were significantly higher than those in the non-recurrence group. The areas under the ROC curve (AUC) were 0.72, 0.65, 0.53, and 0.64 for SLX, CEA, SCC, and CYFRA21-1, respectively. The prognostic cut-off values were 36U/ml, 7.8ng/ml, 1.5ng/ml, and 3.2ng/ml for SLX, CEA, SCC, and CYFRA21-1, respectively. A log-rank test revealed that age, performance status, T factor, lymphatic invasion, vascular invasion, SLX, CEA, SCC, and CYFRA21-1 were all significantly associated with survival. By multivariate analysis, age, performance status, lymphatic invasion, SLX (risk ratio, 4.11) and CYFRA21-1 (risk ratio, 3.47) were independent prognostic factors. For patients positive for both CYFRA21-1 and SLX, the relative risk was 5.32 compared with patients who were negative for both markers. The 5-year survival rates were 80% in the group negative for both markers (n=86); 52% in the group positive for one of the markers (n=43); and 13% for the group positive for both markers (n=8) (p<0.001). We concluded that serum SLX and CYFRA21-1 were prognostic markers for stage I NSCLC. Their combination should contribute to the classification of stage I NSCLC patients. There is a need to consider adjuvant and neoadjuvant therapies to improve prognosis in patients positive for both tumor markers. SN - 0169-5002 UR - https://www.unboundmedicine.com/medline/citation/17697728/Serum_Sialyl_Lewis_x_and_cytokeratin_19_fragment_as_predictive_factors_for_recurrence_in_patients_with_stage_I_non_small_cell_lung_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0169-5002(07)00406-0 DB - PRIME DP - Unbound Medicine ER -